Evidence for Cross-Protection but Not Type-Replacement Over the 11 Years After Human Papillomavirus Vaccine Introduction

Human Vaccines and Immunotherapeutics - United States
doi 10.1080/21645515.2018.1564438
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Closing Editorial: Processes, Opportunities and Challenges After Introduction of Human Papillomavirus Vaccine

Sexual Health
EnvironmentalPublic HealthInfectious DiseasesOccupational Health
2010English

Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine

Drugs
Pharmacology
2011English

S12.1 Human Papillomavirus Vaccines - Correlates of Protection Are Not Defined

Sexually Transmitted Infections
DermatologyInfectious Diseases
2013English

Human Papillomavirus 9-Valent Vaccine for Cancer Prevention: A Systematic Review of the Available Evidence

Epidemiology and Infection
EpidemiologyInfectious Diseases
2017English

Laboratory Production in Vivo of Infectious Human Papillomavirus Type 11.

Journal of Virology
Insect ScienceImmunologyMicrobiologyVirology
1987English

A Novel Vaccine for Cervical Cancer: Quadrivalent Human Papillomavirus (Types 6, 11, 16 and 18) Recombinant Vaccine (Gardasil®)

Therapeutics and Clinical Risk Management
2008English

Protection Against Heterologous Human Papillomavirus Challenge by a Synthetic Lipopeptide Vaccine Containing a Broadly Cross-Neutralizing Epitope of L2

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2008English

Cervical Cancer and the Human Papillomavirus Vaccine

Journal of Family Planning and Reproductive Health Care
2006English

Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine for the Prevention of Genital Warts in Males

Drugs in R and D
Pharmacology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy